Skip to content
About
Clinical Trials
Resources
Contact
Menu
About
Clinical Trials
Resources
Contact
LS-P-GO44479
LS-P-GO44479: A Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran plus Atezolizumab and mFolfirinox versus mFolfirinox Alone in Patients with Respected Pancreatic Ductal Adenocarcinoma
Status:
Open
Trial Type:
Pancreas Cancer
Contact:
Dr. Alex Raufi
araufi2@lifespan.org